BOXED O
WARNING O
: O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
( O
HBV O
) O
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
receiving O
CD20-directed O
cytolytic O
antibodies O
, O
including O
GAZYVA O
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
treatment O
initiation O
. O

Monitor O
HBV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients I-Not_AE_Candidate
during O
and O
after O
treatment O
with O
GAZYVA O
. O

Discontinue O
GAZYVA O
and O
concomitant O
medications O
in O
the O
event O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
including O
fatal O
PML B-OSE_Labeled_AE
, O
can O
occur O
in O
patients O
receiving O
GAZYVA O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Hepatitis O
B O
Virus O
( O
HBV O
) O
reactivation O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis O
, O
hepatic O
failure O
, O
and O
death O
. O

( O
5.1 O
) O
* O
Progressive O
Multifocal O
Leukoencephalopathy O
( O
PML O
) O
resulting O
in O
death O
. O

( O
5.2 O
) O

